

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MURRAY & POOLE ENTERPRISES LTD.,
Petitioner,

v.

INSTITUT DE CARDIOLOGIE DE MONTREAL,
Patent Owner.

Case IPR2023-01064
Patent No. 11,400,063

PETITIONER'S UPDATED EXHIBIT LIST

Pursuant to 37 C.F.R. § 42.63(e), Petitioner Murray & Poole Enterprises Ltd. hereby submits a current listing of Petitioner's exhibits. New exhibits 1050-1080 (except where noted as reserved) are being filed today.

Exhibit	Description
1001	U.S. Patent No. 11,400,063 B2 to Tardif ("the '063 patent")
1002	Certified File History of the '063 patent
1003	Provisional Application 63/093,988 (Oct. 20, 2020)
1004	Provisional Application 62/935,865 (Nov. 15, 2019)
1005	Nadia Bouabdallaoui et al., <i>Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)</i> , 41 Eur. Heart J. 4092-99 (2020)
1006	WayBack Machine archive of Clinical Trials.gov identifier NCT02551094, <i>Colchicine Cardiovascular Outcomes Trial (COLCOT)</i> (COLCOT), https://web.archive.org/web/20171020004013/https://clinicaltrials.gov/ct2/show/NCT02551094 (accessed Apr. 11, 2023)
1007	U.S. Patent No. 10,206,891 B2 to Nidorf ("the '891 patent")
1008	Ulf Stenestrand & Lars Wallentin, <i>Early Statin Treatment Following Acute Myocardial Infarction and 1-Year Survival</i> , 285 J. Am. Med. Ass'n 430-36 (2001)
1009	Borja Ibanez et al., <i>2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation</i> , 39 Eur. Heart J. 119-77 (2018)
1010	Gregg W. Stone, <i>Angioplasty Strategies in ST-Segment-Elevation Myocardial Infarction: Part I: Primary Percutaneous Coronary Intervention</i> , 118 Circulation 538-51 (2008)

1011	Hoang V. Tran et al., <i>Trends in Length of Hospital Stay and the Impact on Prognosis of Early Discharge After a First Uncomplicated Acute Myocardial Infarction</i> , 121 Am. J. Cardiology 397-402 (2018)
1012	Aernoud T. L. Fiolet et al., <i>Colchicine in Acute Coronary Syndrome: When to Commence?</i> , Am. Coll. Cardiology, https://www.acc.org/latest-in-cardiology/articles/2021/09/15/13/23/colchicine-in-acute-coronary-syndrome (accessed June 13, 2023)
1013	Harolyn Baker et al., <i>Regional Hospital Collaboration and Outcomes in Medicare Heart Failure Patients: See You in 7</i> , 3(10) JACC: Heart Failure 765-73 (2015)
1014	Cindy L. Grines et al., <i>Safety and Cost-Effectiveness of Early Discharge After Primary Angioplasty in Low Risk Patients With Acute Myocardial Infarction</i> , 31(5) J. Am. Coll. Cardiology 967-72 (1998)
1015	Aaron W. Aday & Paul M. Ridker, <i>Antiinflammatory Therapy in Clinical Care: The CANTOS Trial and Beyond</i> , 5(62) Frontiers in Cardiovascular Med. 1-6 (2018)
1016	COLCRYS™ [Package Insert] Philadelphia, PA: Mutual Pharmaceutical Company, Inc. (July 2009)
1017	Grant W. Reed et al., <i>Acute myocardial infarction</i> , 389 Lancet 197-210 (2017)
1018	U.S. Patent No. 10,265,281 B2 to Nidorf (“the ’281 patent”)
1019	P.M. Ridker et al., <i>Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease</i> , 377(12) New Eng. J. Med. 1119-31 (2017)
1020	Stefan M. Nidorf et al., <i>Low-Dose Colchicine for Secondary Prevention of Cardiovascular Disease</i> , 61(4) J. Am. Coll. Cardiology 404-10 (2013)
1021	Thomas J. Ryan et al., <i>1999 Update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations: A Report of the</i>

	<i>American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction), 100 Circulation 1016-30 (1999)</i>
1022	Jean-Claude Tardif et al., <i>Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction</i> , 381(26) New Eng. J. Med. 2497-505 (2019)
1023	Jacek Kubica et al., <i>Treatment of patients with acute coronary syndrome: Recommendations for medical emergency teams: Focus on antiplatelet therapies. Updated experts' standpoint</i> , 25(3) Cardiology J. 291-300 (2018)
1024	Yukio Ozaki et al., <i>CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) in 2018</i> , 33 Cardiovascular Intervention & Therapeutics 178-203 (2018)
1025	EUR. SOC'Y OF CARDIOLOGY, ESC CONGRESS 2020: THE DIGITAL EXPERIENCE: 29 AUGUST TO 1 SEPTEMBER: POST-CONGRESS REPORT (2020)
1026	Peter L. Thompson & S. Mark Nidorf, <i>Colchicine: an affordable anti- inflammatory agent for atherosclerosis</i> , 29(6) Current Op. Lipidology 467-73 (2018)
1027	ISIS-2 (Second International Study of Infarct Survival) Collaborative Group, <i>Randomised Trial of Intravenous Streptokinase, Oral Aspirin, Both, or Neither Among 17 187 Cases of Suspected Acute Myocardial Infarction: ISIS-2</i> , 2(8670) Lancet 349-60 (1988)
1028	Thomas Hennessy et al., <i>The Low Dose Colchicine after Myocardial Infarction (LoDoCo-MI) study: A Pilot randomized placebo controlled trial of colchicine following acute myocardial infarction</i> , Am. Heart J. 215:62-69 (2019)
1029	Kaivan Vaidya et al., <i>Colchicine Therapy and Plaque Stabilization in Patients With Acute Coronary Syndrome: A CT Coronary Angiography Study</i> , 11(2) JACC: Cardiovascular Imaging 305-16 (2018)

1030	Subodh Verma et al., <i>Colchicine in cardiac disease: a systematic review and meta-analysis of randomized controlled trials</i> , 15 BMC Cardiovascular Disorders 96 (2015)
1031	Clinical Trials.gov identifier NCT02551094, <i>History of Changes for Study: NCT02551094: Colchicine Cardiovascular Outcomes Trial (COLCOT) (COLCOT)</i> , https://clinicaltrials.gov/ct2/history/NCT02551094?A=1&B=3&C=Side-by-Side#StudyPageTop (accessed Apr. 23, 2023)
1032	Borja Ibañez & Valentin Fuster, <i>CANTOS: A Gigantic Proof-of-Concept Trial</i> , 121 Circulation Rsch. 1320-22 (2017)
1033	Richard A. Baylis et al., <i>The CANTOS Trial: One Important Step for Clinical Cariology but a Giant Leap for Vascular Biology</i> , 37(11) Arteriosclerosis, Thrombosis, & Vascular Biology e174-e177 (2017)
1034	Subodh Verma et al., <i>CANTOS Ushers in a New Calculus of Inflammasome Targeting for Vascular Protection – and Maybe More</i> , 26 Cell Metabolism 703-05 (2017)
1035	Christian Weber & Philipp von Hundelshausen, <i>CANTOS Trial Validates the Inflammatory Pathogenesis of Atherosclerosis: Setting the Stage for a New Chapter in Therapeutic Targeting</i> , 121(10) Circulation Rsch. 1119-21 (2017)
1036	UNITED STATES PHARMACOPEIAL CONVENTION, THE UNITED STATES PHARMACOPEIA, “Colchicine” 38 USP 2934-36 (2015)
1037	European Patent Office File History of Application Number EP19209545.3
1038	Declaration of Raymond Cruitt, M.S.
1039	Paul M Ridker et al., <i>Antiinflammatory therapy with canakinumab for atherosclerotic disease, Protocol</i> , 377 New Eng. J. Med. 1119-31 (2017)
1040	Spyridon Deftereos et al., <i>Anti-Inflammatory Treatment With Colchicine in Acute Myocardial Infarction: A Pilot Study</i> , 132

	Circulation 1395-1403 (2015)
1041	Gonzalo J. Martínez et al., <i>Colchicine Acutely Suppresses Local Cardiac Production of Inflammatory Cytokines in Patients With an Acute Coronary Syndrome</i> , 4(8) J. Am. Heart Ass'n e002128 (2015)
1042	Stefano Toldo & Antonio Abbate, <i>The NLRP3 inflammasome in acute myocardial infarction</i> , 15(4) Cardiology 203-14 (2018)
1043	Stefan M. Nidorf & Subodh Verma, <i>Is There a Role for Colchicine in Acute Coronary Syndromes?</i> , 4(8) J. Am. Heart Ass'n e002372 (2015)
1044	Georgios Tsivgoulis et al., <i>The Role of Colchicine in the Prevention of Cerebrovascular Ischemia</i> , 24 Current Pharm. Design 668-74 (2018)
1045	WayBack Machine archive of Clinical Trials.gov identifier NCT02898610, <i>Colchicine for Prevention of Vascular Inflammation in Non-cardio Embolic Stroke (CONVINCE)</i> , https://web.archive.org/web/20191214125501/https://clinicaltrials.gov/ct2/show/NCT02898610 (accessed June 1, 2023)
1046	WayBack Machine archive of Clinical Trials.gov identifier NCT03048825, <i>Colchicine and Spironolactone in Patients With STEMI/SYNERGY Stent Registry (CLEAR-SYNERGY)</i> , https://web.archive.org/web/20190507114813/https://clinicaltrials.gov/ct2/show/NCT03048825 (accessed June 1, 2023)
1047	Stefan Mark Nidorf & Peter Lindsay Thompson, <i>Why Colchicine Should Be Considered for Secondary Prevention of Atherosclerosis: An Overview</i> , 41(1) Clinical Therapeutics 41-48 (2019)
1048	Australian New Zealand Clinical Trials Registry, <i>The effect of Colchicine on Cardiovascular Outcomes in Acute Coronary Syndrome Study (The COLCARDIO-ACS Study)</i> , https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=370284&isReview=true (accessed June 1, 2023)
1049	Declaration of Paul Ridker, M.D.
1050	Transcript of Conference Call with Board (May 30, 2024)

1051	“CADTH Reimbursement Recommendation, Colchicine (Myinfla),” 2(3) Canadian J. of Health Techs. (2022)
1052	“CADTH Reimbursement Review, Stakeholder Feedback on Draft Recommendation, Colchicine (Myinfla)” (Dec. 2, 2021)
1053	“CADTH Reimbursement Review, Colchicine (Myinfla),” 2(4) Canadian J. of Health Techs. (2022)
1054	Atorvastatin (Lipitor) Prescribing Label (2019)
1055	Rosuvastatin (Crestor) Prescribing Label (2023)
1056	<i>Reserved</i>
1057	LoDoCo Prescribing Label (2023)
1058-1059	<i>Reserved</i>
1060	COLCOT Clinical Research Protocol # MHIPS-003 (June 1, 2015)
1061	<i>Reserved</i>
1062	Supplementary Appendix to Tardif J-C et al., <i>Efficacy and safety of low-dose colchicine after myocardial infarction</i> . 381 New Eng. J. Med. 2497-2505 (2019)
1063-1065	<i>Reserved</i>
1066	Nadia Bouabdallaoui and Jean-Claude Tardif, <i>Initiation of low-dose colchicine early after myocardial infarction</i> , 42 Eur. Heart J. 2798-2799 (2021)
1067	Peter Sleight, <i>Debate: Subgroup analyses in clinical trials – fun to look at, but don’t believe them!</i> , 1 Curr Control Trials Cardiovasc Med 25–27 (July 31, 2000)
1068	Susan F. Assmann et al, <i>Subgroup analysis and other (mis)uses of baseline data in clinical trials</i> , 255 Lancet 1064-1069 (2000)

1069	Nadia Bouabdallaoui et al., <i>Impact of smoking on cardiovascular outcomes in patients with stable coronary artery disease</i> , Euro. J. Preventive Cardiology (prepubl. Manuscript) (Aug. 6, 2020)
1070	<i>Reserved</i>
1071	Nadia Bouabdallaoui et al., <i>Impact of Intubation Time on Survival following Coronary Artery Bypass Grafting: Insights from the Surgical Treatment for Ischemic Heart Failure (STICH) trial</i> , 32(3) J. Cardiothorac Vasc. Anesth., 1256–1263 (2018)
1072	Second Declaration of Raymond Cruitt, M.S. (July 8, 2024)
1073	Declaration of James L. Mullins, Ph.D. (June 28, 2024)
1074	RMS Final Assessment Report of MyInfla® (Mar. 13, 2024)
1075	Second Declaration of Paul Ridker, M.D. (July 11, 2024)
1076	Transcript of Deposition of Dr. Hossein Ardehali, M.D. (June 18, 2024)
1077	Transcript of Deposition of Dr. Jean-Claude Tardif, M.D. (June 26, 2024)
1078	Transcript of Deposition of Dr. Bouabdallaoui, M.D., Ph.D. (June 28, 2024)
1079	Guillaume Marquis-Gravel et al., <i>Colchicine for Prevention of Atherothrombotic Events in Patients With Coronary Artery Disease: Review and Practical Approach for Clinicians</i> , 37 Canadian Journal of Cardiology 1837-1845 (2021)
1080	Clean copy of EX1012
1081	Declaration of Joanna T. Brougher (July 30, 2024) [<i>SERVED BUT NOT FILED</i>]
1082	Murray & Poole’s Demonstrative Exhibits for Oral Argument

2024 Oct. 10

Joanna Brougher

Joanna T. Brougher, Reg. No. 62,640

CERTIFICATE OF SERVICE

I hereby certify that on October 10, 2024, copies of the foregoing PETITIONER'S UPDATED EXHIBIT LIST and Exhibit 1082 were served via electronic mail to counsel for the patent owner, as consented to by counsel, upon the following counsel for the petitioner:

Sailesh K. Patel: Sailesh.patel@afslaw.com_

Imron T. Aly: Imron.aly@afslaw.com_

Matthew T. Wilkerson: Matthew.wilkerson@afslaw.com_

Joanna Brougher

Joanna T. Brougher

Registration No. 62,640